Evelo Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EVLO research report →
About the company
Evelo Biosciences, Inc. is a biotechnology firm dedicated to identifying and advancing oral biologic therapies for various inflammatory conditions and oncological diseases. Its pipeline includes EDP1815, a whole-microbe compound designed to address inflammatory ailments, currently undergoing Phase 2 clinical trials for conditions such as psoriasis and atopic dermatitis, and also being evaluated for the hyperinflammatory reaction associated with COVID-19.
- CEO
- Craig R. Jalbert
- IPO
- 2018
- Employees
- 66
- HQ
- Cambridge, MA, US
Price Chart
- Market Cap
- $1.90K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.03
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -6232.76%
- ROIC
- -191.76%
- Revenue
- $0 · 0.00%
- Net Income
- $-114,527,000 · 6.26%
- EPS
- $-26.28 · 43.09%
- Op Income
- $-108,466,000
- FCF YoY
- -3.68%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.31
- Avg Volume
- 503
Get TickerSpark's AI analysis on EVLO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 7, 23 | Bodmer Mark | other | 6,625 |
| Nov 8, 23 | Bodmer Mark | sell | 3,163 |
| Nov 7, 23 | Bodmer Mark | other | 6,625 |
| Nov 7, 23 | McHale Duncan | other | 6,500 |
| Nov 8, 23 | McHale Duncan | sell | 3,103 |
| Nov 7, 23 | McHale Duncan | other | 6,500 |
| Nov 7, 23 | GILL SIMBA | other | 1,172 |
| Nov 8, 23 | GILL SIMBA | sell | 172 |
| Nov 7, 23 | GILL SIMBA | other | 1,172 |
| Nov 7, 23 | Thorell Marella | other | 6,500 |
Our EVLO coverage
Recent articles, reports, and earnings notes.
No research on EVLO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EVLO report →Similar companies
Peers in the same neighborhood.